Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
IBDretrospective · n=10,482 · Nov 7, 2026 · J of Crohn's and Colitis · IF 8.3
New evidenceCrohn's diseaseperianal diseasebiologicsJAK inhibitors
Clinical takeawayWhen perianal complications are a concern in non-penetrating Crohn's disease, weigh this claims-data association favouring a TNF antagonist or ustekinumab over vedolizumab; it held in advanced-therapy-naive and previously exposed patients.
What it foundTNF antagonists (HR 0.56) and ustekinumab (HR 0.62) were associated with lower risk of perianal penetrating complications compared to vedolizumab in non-penetrating Crohn's disease, both in advanced-therapy-naive and prior AT exposure subgroups.
ContextRefines current practice by comparing advanced therapies for perianal complication risk in non-penetrating Crohn's disease, highlighting subgroups with prior AT exposure.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
Clinical takeawayIn suspected ICI enterocolitis, grade by CTCAE, test stool for pathogens and calprotectin, and perform endoscopy with biopsies and imaging when indicated. Start corticosteroids (mild or microscopic disease may respond to budesonide or beclomethasone), escalate early to infliximab or vedolizumab if steroid-refractory or dependent, and consider ICI rechallenge after multidisciplinary review.
What it foundTwenty-three ECCO Current Practice Positions on drug-induced enterocolitis; drug colitis can show IBD-like, acute, microscopic, ischemic-type or mixed patterns, none pathognomonic.
ContextClose clinicopathological collaboration is needed because no histological pattern is pathognomonic; surgery is reserved for refractory or complicated cases.
Reinforcessuggested applicable standard· American Gastroenterological Association (AGA), "AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review" (Dougan M, Wang Y, Rubio-Tapia A, Lim JK), Gastroenterology 2021;160(4):1384-1393ShowHide
…In grade 2 or higher colitis/diarrhea, early stool inflammatory markers (lactoferrin, calprotectin) may help stratify patients for endoscopy, and endoscopic confirmation of the diagnosis and severity should be considered before starting high-dose systemic glucocorticoids; abdominal imaging is reserved for dominant pain, fever, or bleeding and should not be done routinely for diarrhea alone.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
For suspected ICI colitis, exclude infectious causes of diarrhea (including C. difficile) before treating. In grade 2 or higher colitis/diarrhea, early stool inflammatory markers (lactoferrin, calprotectin) may help stratify patients for endoscopy, and endoscopic confirmation of the diagnosis and severity should be considered before starting high-dose systemic glucocorticoids; abdominal imaging is reserved for dominant pain, fever, or bleeding and should not be done routinely for diarrhea alone. The AGA cautions that no validated severity index for ICI colitis exists and that symptoms correlate poorly with endoscopic, radiologic, and treatment-response severity, and that rapid progression over days can occur, particularly with ipilimumab. ICI colitis typically responds to high-dose systemic glucocorticoids at 0.5-2 mg/kg prednisone-equivalent daily tapered over 4-6 weeks (the AGA explicitly notes these doses and schedules have not been rigorously examined). If there is no improvement after 2-3 days, add infliximab or vedolizumab while continuing glucocorticoids; both are reasonable options for glucocorticoid-refractory colitis. Budesonide is ineffective as prophylaxis and is not a standard treatment for ICI colitis, it is reserved for ICI-associated microscopic colitis. Retreatment with immunotherapy is possible under select conditions. For hepatitis, obtain baseline liver chemistries (total bilirubin, alkaline phosphatase, AST, ALT) and HBV serologies before ICI; grade by CTCAE and manage as follows: grade 1 (AST/ALT 1-3x ULN or bilirubin 1-1.5x ULN), monitor liver chemistries 1-2 times weekly; grade 2 (AST/ALT >3-5x ULN or bilirubin >1.5-3x ULN), hold ICI until resolution to grade 1, and if symptomatic give prednisone 0.5-1.0 mg/kg/d or equivalent; grade 3 (AST/ALT >5-20x ULN or bilirubin >3-10x ULN), discontinue ICI and start methylprednisolone 1-2 mg/kg/d or equivalent; grade 4 (AST/ALT >20x ULN or bilirubin >10x ULN or hepatic decompensation), permanently discontinue ICI and start methylprednisolone 2 mg/kg/d. For ICI hepatitis that does not adequately improve after 3-5 days of high-dose glucocorticoids, escalate to a second-line immunosuppressant, mycophenolate mofetil (with azathioprine as an accepted alternative), while continuing glucocorticoids; infliximab is not recommended for ICI hepatitis because of its potential for hepatotoxicity. Evaluate all ICI-related liver-chemistry elevations for alternate etiologies (consider liver biopsy), and obtain biliary imaging when alkaline phosphatase and/or bilirubin are elevated.
New evidenceperianal diseaseCrohn's diseaseartificial intelligence
Clinical takeawayConsider NC-MRI as a reasonable alternative to CE-MRI for detecting and grading perianal fistulas in Crohn's disease patients who cannot receive contrast or for abbreviated exams, but CE-MRI remains superior for complex disease.
What it foundNC-MRI detected index fistulas in 115/145 patients (79%) vs 117/145 (81%) on CE-MRI, with 96% sensitivity and 93% specificity for index fistula detection.
ContextConfirms NC-MRI as a viable alternative to CE-MRI for initial fistula detection and grading, though CE-MRI has added value for assessing complex perianal disease, including secondary fistulas and tracts.
Refinessuggested applicable standard· American Society of Colon and Rectal Surgeons (ASCRS), "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula" (Gaertner WB, Burgess PL, Davids JS, et al.), Diseases of the Colon & Rectum 2022;65(8):964-985, doi:10.1097/DCR.0000000000002473ShowHide
Decision at stakethe use of MRI for diagnosing perianal fistulas in Crohn's disease
…Routine diagnostic imaging is NOT typically necessary (1B); reserve imaging for selected patients with occult abscess, recurrent or complex fistula, immunosuppression, or anorectal Crohn's disease (MRI sensitivity 97% vs 74% for endoanal ultrasound in complex fistula; combined accuracy approaches 100%).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Diagnose anorectal abscess and fistula-in-ano clinically: a disease-specific history and physical examination assessing symptoms, relevant history, abscess and fistula location, and secondary cellulitis (1C), with digital rectal exam and anoscopy/proctoscopy as needed. Routine diagnostic imaging is NOT typically necessary (1B); reserve imaging for selected patients with occult abscess, recurrent or complex fistula, immunosuppression, or anorectal Crohn's disease (MRI sensitivity 97% vs 74% for endoanal ultrasound in complex fistula; combined accuracy approaches 100%). Treat acute anorectal abscess promptly with incision and drainage (1C), placing the incision close to the anal verge to limit subsequent tract length and preserve the sphincter complex; packing is not required and unpacked wounds gave better resolution, less pain and faster healing in randomized trials. Reserve antibiotics for abscess complicated by cellulitis, systemic signs of infection, or underlying immunosuppression (2B); routine antibiotics after uncomplicated drainage in healthy patients do not improve healing or reduce recurrence, and conversely immunosuppressed patients with low neutrophil counts and no fluctuance may initially be treated with antibiotics alone rather than drainage. Concomitant fistulotomy at the time of drainage may be performed in selected patients with a simple anal fistula (2B), balancing lower recurrence (RR 0.13 in a 479-patient meta-analysis) against a non-significant increase in continence disturbance. For simple fistula-in-ano with normal sphincter function, lay-open fistulotomy heals over 90% (1B); for low fistulas involving less than one third of the external sphincter the clinically significant incontinence risk is minimal, and marsupialization improves healing and reduces bleeding. Sphincter-preserving options: endorectal advancement flap (1B; 66% to 87% initial healing, but up to 35% mild-to-moderate incontinence) and, for transsphincteric tracts, ligation of the intersphincteric fistula tract (LIFT) (1B; 76% pooled success, 1.4% incontinence). A cutting seton may be used selectively for complex cryptoglandular fistula (2C, downgraded from 2B; reported incontinence ranges 0% to 67%). The anal fistula plug and fibrin glue are relatively ineffective (1B, upgraded from 2B; contemporary healing 50% or less). Endoscopic or laser closure techniques (VAAFT, FiLaC, OTSC) have reasonable short-term healing but unknown long-term healing and recurrence rates (2C). In Crohn's disease, where abscess and fistula arise from penetrating inflammation rather than cryptoglandular infection, management is multidisciplinary and a draining seton is typically useful and may be used for long-term disease control (1B, upgraded from 1C); Crohn's disease is a named risk factor for failure or recurrence of fistulotomy, advancement flap, LIFT, and plug.
New evidenceulcerative colitishealth servicesepidemiologycost-effectiveness
Clinical takeawayKeep strictures and obstruction in mind as an uncommon UC complication, especially in older patients and those with comorbidities; the higher rate with advanced therapy is a retrospective association, not evidence of drug harm.
What it found1.4% of UC patients developed fibrotic complications, with older age (HR=2.75 for >65 vs. 18-40), comorbidities (HR=1.73), and advanced therapy exposure (HR=4.38) increasing risk.
ContextChallenges the traditional view of UC as non-fibrostenosing, highlighting fibrotic complications as a significant clinical and healthcare burden in patients aged 41 and older with comorbidities or advanced therapy exposure.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
Decision at stakethe clinical decision to manage fibrotic complications in ulcerative colitis
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
Shapiro I … Ben-Tov A · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
IBDprospective cohort · n=57 · Nov 5, 2026 · Inflamm Bowel Dis · IF 4.5
Basic sciencebiologicstherapeutic drug monitoringartificial intelligencebiomarker
Clinical takeawayCapillary self-collection devices for infliximab trough level monitoring show promise in IBD patients, but further validation and availability are needed before clinical implementation.
What it foundCapillary self-collection of infliximab trough levels correlated strongly with venous blood measurement (R2 = 0.987, Demings = 1.08).
ContextThis feasibility study in 57 IBD patients (median age 34 years) at a single center demonstrates that capillary self-collection yields results comparable to venous blood sampling.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Law CCY … Colombel JF · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBDprospective cohort · n=1,234 · Nov 4, 2026 · Inflamm Bowel Dis · IF 4.5
New evidenceepidemiologyCrohn's diseaseulcerative colitishealth services
Clinical takeawayAsk about work early in newly diagnosed IBD, especially Crohn's disease at ages 30 to 39; lower self-efficacy and quality of life, not disease activity, were associated with work disability, a possible target for interventions.
What it foundAt 1 year, UC and CD patients had increased risk of AAP compared to the background population (UC RR 1.6, CD RR 3.6), but DP risk was comparable.
ContextConfirms and quantifies the increased risk of WD in IBD patients, particularly AAP, and identifies modifiable factors (self-efficacy, quality of life) associated with WD.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Lund C … Høivik ML · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBDretrospective · n=68 · Nov 5, 2026 · Inflamm Bowel Dis · IF 4.5
Guideline / reviewbiomarkerCrohn's diseaseulcerative colitistherapeutic drug monitoring
Clinical takeawayContinue using FC as the primary biomarker to assess inflammation in pregnant women with IBD in remission, as it remains stable and reliable throughout pregnancy. Interpret ESR, CRP, and CBC changes cautiously, recognizing they may reflect physiologic pregnancy changes rather than disease activity.
What it foundFecal calprotectin (FC) remained stable and within normal range throughout pregnancy in women with IBD in remission (all P > .05), while ESR, CRP, and CBC markers showed significant trimester-specific changes.
ContextConfirms FC's established reliability in pregnancy, reinforcing its role as the most stable biomarker in this population. Highlights the need for cautious interpretation of ESR and CRP, which are less specific during pregnancy.
Emergingsuggested applicable standard· American Gastroenterological Association, 'Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group' (Mahadevan U et al., Gastroenterology 2019;156(5):1508-1524). DOI 10.1053/j.gastro.2018.12.022, PMID 30658060.ShowHide
In IBD patients who are pregnant or planning pregnancy, the goal remains stable steroid-free remission before conception, throughout pregnancy, and postpartum, because active disease (not medication) is the dominant driver of adverse maternal/fetal outcomes (preterm birth, growth restriction, low birth weight, hypertensive disease, cesarean birth).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
In IBD patients who are pregnant or planning pregnancy, the goal remains stable steroid-free remission before conception, throughout pregnancy, and postpartum, because active disease (not medication) is the dominant driver of adverse maternal/fetal outcomes (preterm birth, growth restriction, low birth weight, hypertensive disease, cesarean birth). Continue effective maintenance therapy on schedule through pregnancy and lactation, mesalamine, thiopurines, and biologics/biosimilars (anti-TNF, vedolizumab, ustekinumab), rather than stopping for pregnancy; discontinuation raises postpartum flare and complication risk. SCOPE OF THE CITED SOURCE, read this before extending the sentence above: the IL-23p19 antagonists are NOT addressed by the 2019 AGA IBD Parenthood Project pathway, which predates their IBD indications entirely (Drugs@FDA efficacy-supplement approvals: risankizumab for Crohn's disease June 2022 and for ulcerative colitis June 2024; mirikizumab for ulcerative colitis October 2023 and for Crohn's disease January 2025; guselkumab for ulcerative colitis September 2024 and for Crohn's disease March 2025). Continuing risankizumab, guselkumab or mirikizumab through pregnancy and lactation is EXPERT PRACTICE extrapolated from the other monoclonal antibodies, it is not a recommendation of the cited document, and it must not be presented as one. All three FDA labels state that the available human pregnancy data are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes, and all three carry a pregnancy exposure registry: enrol the patient and document the shared decision. Avoid JAK inhibitors during pregnancy and lactation due to insufficient reproductive safety data. For suspected flare, favor fecal calprotectin plus intestinal ultrasound or non-gadolinium MRI over CT, reserve endoscopy for when it will change management, and use corticosteroids or biologic initiation/switching as clinically necessary. Recommend cesarean delivery for active perianal Crohn's disease and now also consider cesarean for patients with a prior ileal pouch-anal anastomosis (IPAA) to protect pouch function. New elements versus prior guidance: low-dose aspirin started at 12-16 weeks gestation to reduce preeclampsia risk, structured VTE risk monitoring pre-delivery and postpartum, and explicit endorsement of breastfeeding while on biologic therapy. Multidisciplinary GI/MFM coordination is maintained throughout.
New evidenceCrohn's diseasebiologicsanti-TNFvedolizumab
Clinical takeawayNo change yet: early initiation trended toward greater persistence but did not reach significance (HR 0.61, 95% CI 0.35-1.09); the authors call for prospective confirmation.
What it found36-month persistence rates for infliximab, adalimumab, ustekinumab, and vedolizumab were 77.5%, 75.7%, 79.8%, and 49.0%, respectively; early initiation trended toward greater persistence compared to delayed initiation (HR 0.61, 95% CI 0.35-1.09).
ContextInterim analysis of a national inception registry; 74% of 672 patients started an advanced therapy, 60% within a year of diagnosis.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
New evidenceJAK inhibitorsulcerative colitisCrohn's diseasebiomarker
Clinical takeawayMonitor lipid profiles and assess cardiovascular risk individually in patients with moderate-to-severe IBD on upadacitinib, as TC and LDL-C rise modestly alongside inflammation resolution; note rare adverse events (1 venous thromboembolism, 3 hypertension cases).
What it foundTotal cholesterol rose from 4.19 mmol/L at baseline to 5.21 mmol/L at 2 years (mixed-effects estimates +0.70 to +0.90; all P < .001), with LDL-C and HDL-C rising in parallel and CRP reductions correlating with lipid rises (Spearman rho = -0.45 to -0.47; all P ≤ .02).
ContextConfirms JAK inhibitors' known lipid effects but provides real-world longitudinal data specific to upadacitinib in IBD, linking lipid changes to inflammation reduction.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.
New evidenceulcerative colitisperianal diseaseepidemiologybiologics
Clinical takeawayAsk about perianal symptoms in UC, especially in men and patients with extra-intestinal manifestations (OR 1.32 and 1.88); ulcerative proctitis was protective (OR 0.66).
What it foundPerianal disease (PD) occurred in 4% of UC patients, with 22% developing PD before UC diagnosis; fissures (52%), fistulae (44%), and abscesses (39%) were the most common lesions.
ContextRetrospective registry of 9,884 UC patients; the authors judge UC perianal disease less aggressive than in Crohn's disease, managed mostly conservatively or with perianal surgery (44%).
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
New evidencepediatricperianal diseaseCrohn's diseasebiologics
Clinical takeawayConsider genetic testing for monogenic mutations, particularly IL-10RA, in VEO-IBD patients with perianal disease. Thalidomide and/or HSCT may be individualized options for selected monogenic VEO-IBD patients, but avoid generalizing thalidomide to all VEO-IBD.
What it foundVEO-IBD with PD had a monogenic mutation rate of 77.27% (17/22), predominantly IL-10RA, and lower clinical remission (71.93% vs 95.40% in non-PD).
ContextConfirms that VEO-IBD with PD is associated with monogenic mutations and poorer outcomes, refining prior evidence on disease severity and treatment response in pediatric CD. Highlights the need for cautious use of thalidomide in this population.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Clinical takeawayNo clinical action yet: a mechanistic finding in peripheral blood immune phenotypes. Prospective studies are needed to determine predictive utility.
What it foundVDZ responders showed enrichment of an α4β7+ effector memory CD4+ T-cell subset and reduced frequencies of class-switched plasmablast and activated B-cell populations compared to VDZ-naive UC.
ContextOpens a question: identifies potential immune correlates of VDZ response and non-response in UC, which were previously unidentified.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)ShowHide
Decision at stakeidentifying correlates of response to vedolizumab in ulcerative colitis
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.
Clinical takeawayNo clinical action yet: a retrospective cohort study showing IBD patients may have fewer oral irAEs on ICIs, possibly due to the protective effects of concurrent IBD therapies, but no specific management changes are supported.
What it foundIBD patients on ICIs had fewer oral irAEs (specific symptoms and lesion frequency) and less supportive care use compared to non-IBD patients.
ContextAddresses whether IBD predisposes to oral checkpoint-inhibitor toxicity; IBD patients had fewer oral irAEs, and ICI therapy was paused in similar proportions.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Wali S … Wang Y · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBDprospective cohort · n=190 · Nov 7, 2026 · J of Crohn's and Colitis · IF 8.3
Clinical takeawayNo clinical action yet: a mechanistic finding on microbial resistance patterns in pouchitis. Consider integrating plasmid analysis into metagenome-based approaches for personalized antibiotic treatment in future research.
What it foundE. coli in SickPouch had significantly higher ciprofloxacin resistance mutations (gyrA and parC genes) compared to HealthyPouch (P < .05) and NormalGut (P < .05).
ContextChallenges the assumption that FMT from a healthy colon microbiome is optimal for pouchitis, suggesting HealthyPouch microbiota may be more appropriate. Opens a question on antibiotic resistance monitoring in pouchitis.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Dall SM … Albertsen M · Journal of Crohn's and Colitis · IF 8.3 · PubMed ↗Permalink
IBDprospective cohort · n=33 · Nov 1, 2026 · UEG Journal · IF 5.6
Clinical takeawayNo clinical action yet: mechanistic findings in human tissue and ex vivo models suggest anti-TNF therapy induces molecular changes in CrF, but functional significance remains unclear.
What it foundAnti-TNF-treated Crohn's disease patients showed higher UCP1 expression in creeping fat (CrF) at mRNA and protein levels, with increased browning-/thermogenesis- and mitochondrial biogenesis-associated gene expression in CrF-derived mature adipocytes.
ContextThis study identifies CrF as an anti-TNF-responsive immunometabolic compartment in Crohn's disease, refining understanding of its role in inflammation and therapy response.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Monfort-Ferré D … Serena C · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
IBDprospective cohort · n=34 · Nov 5, 2026 · Inflamm Bowel Dis · IF 4.5
New evidenceartificial intelligencehealth services
Clinical takeawayNo clinical action yet: a pilot study showing feasibility and acute symptom reduction in a single session. Further trials are needed to assess sustained efficacy and integration into care.
What it foundA single AI-driven virtual reality CBT session reduced pain by 0.46 points (P=0.011) and anxiety by 10.65 points (P<0.001) immediately post-session in IBD patients.
ContextExploratory evidence for a novel digital adjunct to traditional mental health support in IBD, addressing known barriers to CBT access.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
George AT … Rubin DT · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
IBDprospective cohort · n=30 · Nov 7, 2026 · J of Crohn's and Colitis · IF 8.3
Clinical takeawayNo clinical action yet: a mechanistic finding in human and mouse models of Crohn's disease.
What it foundB cell/adipocyte crosstalk in Crohn's disease-associated adipose tissue increases MCP-1 secretion and promotes M2-like macrophage polarization.
ContextThis study provides mechanistic insights into the role of B cell/adipocyte interactions in Crohn's disease-associated adipose tissue inflammation, a previously understudied area.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)ShowHide
Decision at stakethe role of B cell/adipocyte crosstalk in Crohn's disease-associated adipose tissue inflammation
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.